Načítá se...
What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review
BACKGROUND: Psilocybin is a predominant agonist of 5HT(1A) and 5HT(2A/C) receptors and was first isolated in 1958, shortly before it became a controlled substance. Research on the potential therapeutic effects of this compound has recently re-emerged alongside what is being addressed as a psychedeli...
Uloženo v:
| Vydáno v: | Porto Biomed J |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Lippincott Williams & Wilkins
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8055489/ https://ncbi.nlm.nih.gov/pubmed/33884324 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/j.pbj.0000000000000128 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|